Skip to main content
Premium Trial:

Request an Annual Quote

Affy, Basking in AmpliChip Approval, Signs J&J Unit as IVD Customer

NEW YORK, Dec. 28 (GenomeWeb News) - Yesterday's US Food and Drug Administration approval of the AmpliChip is already paying dividends for Affymetrix.


Today, the Santa Clara, Calif.-based microarray giant said it has given a Johnson & Johnson company "long-term and comprehensive" access to its GeneChip technology to create and market in vitro diagnostics for certain undisclosed cancers.

The agreement gives Veridex non-exclusive rights to Affy's arrays and instruments. Financial terms of the agreement were not disclosed.


As GenomeWeb News reported yesterday, the FDA cleared Roche's long-awaited AmpliChip CYP450 DNA chip and Affy's GeneChip 3000Dx chip reader as an in vitro diagnostic.


The approval, announced in an FDA statement on Dec. 23, marks the first time that a DNA chip reader has won FDA clearance for IVD use. The agency also said the clearance may open the door for additional molecular diagnostics based on microarrays to be sold nationwide.


The chip and its reader were approved for sale in the European Union in September.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.